| scholarly article | Q13442814 |
| P50 | author | Rafal Kaminski | Q59688197 |
| Kamel Khalili | Q87966397 | ||
| Pietro Mancuso | Q103027524 | ||
| P2093 | author name string | Chen Chen | |
| Fatah Kashanchi | |||
| Shohreh Amini | |||
| Tracy Fischer | |||
| Rahsan Sariyer | |||
| Pasquale Ferrante | |||
| Won-Bin Young | |||
| Ramona Bella | |||
| Jeffrey M. Jacobson | |||
| P2860 | cites work | Effect of transcription peptide inhibitors on HIV-1 replication | Q39549994 |
| In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models | Q40263108 | ||
| A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures | Q40410004 | ||
| Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study | Q40668686 | ||
| Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. | Q40829178 | ||
| Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells | Q41265657 | ||
| Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV. | Q47555333 | ||
| Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. | Q53454854 | ||
| RNA-guided human genome engineering via Cas9 | Q24598394 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents | Q28079455 | ||
| Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy | Q29615993 | ||
| RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. | Q34025414 | ||
| Is the central nervous system a reservoir of HIV-1? | Q34434339 | ||
| Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus | Q34655645 | ||
| Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape | Q36216276 | ||
| Exosomes from HIV-1-infected Cells Stimulate Production of Pro-inflammatory Cytokines through Trans-activating Response (TAR) RNA | Q36466170 | ||
| Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production | Q36547664 | ||
| Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing | Q36650962 | ||
| Persistent HIV-1 replication maintains the tissue reservoir during therapy | Q36897321 | ||
| Tissue reservoirs of HIV | Q37055454 | ||
| A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. | Q38759997 | ||
| CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. | Q38779072 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | CRISPR | Q412563 |
| drug discovery | Q1418791 | ||
| molecular medicine | Q3523816 | ||
| P304 | page(s) | 275-282 | |
| P577 | publication date | 2018-06-19 | |
| P1433 | published in | Molecular Therapy. Nucleic acids | Q27724110 |
| P1476 | title | Removal of HIV DNA by CRISPR from Patient Blood Engrafts in Humanized Mice. | |
| P478 | volume | 12 |
| Q90071246 | A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System |
| Q103027539 | CRISPR based editing of SIV proviral DNA in ART treated non-human primates |
| Q59351019 | CRISPR-Cas Biology and Infectious Diseases Applications |
| Q90523078 | CRISPR-Cas9 Dual-gRNA Attack Causes Mutation, Excision and Inversion of the HIV-1 Proviral DNA |
| Q60954918 | CRISPR/Cas9 Genome Editing to Disable the Latent HIV-1 Provirus |
| Q101476290 | CRISPR/Cas9 as an antiviral against Orthopoxviruses using an AAV vector |
| Q64073285 | CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge |
| Q99237752 | Designing Safer CRISPR/Cas9 Therapeutics for HIV: Defining Factors That Regulate and Technologies Used to Detect Off-Target Editing |
| Q92871298 | Elimination of infectious HIV DNA by CRISPR-Cas9 |
| Q92177909 | Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1+ and TIGIT+ CD4 T Cells |
| Q92134571 | Measuring the Success of HIV-1 Cure Strategies |
| Q89957160 | Pathways towards human immunodeficiency virus elimination |
| Q89659572 | Reduce and Control: A Combinatorial Strategy for Achieving Sustained HIV Remissions in the Absence of Antiretroviral Therapy |
| Q78878955 | Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice |
| Q92912382 | Strong In Vivo Inhibition of HIV-1 Replication by Nullbasic, a Tat Mutant |
| Q64100645 | The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape |
| Q90152125 | The Potential Use of the CRISPR-Cas System for HIV-1 Gene Therapy |
Search more.